Sightegy is a Zürich company. We build Kairos, decision intelligence for biotech, and advise on the decisions it informs.
Our mission
Kairos began as my own frustration. Building ventures, I had to make positioning and partnering calls without a business-development team, from evidence scattered across trial registries, filings and deal announcements. And I saw colleagues with excellent science face the same calls, with no access to the tools large pharma takes for granted. Sightegy exists so that early-stage teams don't have to.
Bogdan RivoalFounder, SightegyLarge pharma has whole strategy teams for the calls that make or break a programme. Most early-stage biotechs still make them on slide decks and instinct.
Sightegy was founded in Zürich in July 2025 to close that gap. It builds Kairos.
The decisions we exist for
Principles
The difference between an opinion and a decision you can defend in front of a board.
If a claim cannot open the passage it came from, it does not belong in a decision.
Language models read and propose. A probability belongs to a model that shows every step it took.
A base rate that forgets the ventures that dissolved flatters everyone. The failures belong in the count.
Write the forecast down before the outcome, with a date. Then let the outcome grade it.
What we build
Kairos for the decision itself, with every line traced to its source.
Sightegy's decision-intelligence platform for biotech. Language models read the evidence; you see what every answer rests on, what is contested, and what Kairos refused to guess.
15+ public sources · 150+ agent tools
Explore Kairos
The founder
FounderStrategic Advisor & AI Platform Architect
Scientist, strategist, AI architect.
A molecular biologist with 15+ years in RNA biology, oncology and liquid biopsy. After a PhD at Institut Pasteur / Sorbonne and a postdoc at Institut Curie, Bogdan founded and led the RNA Biology group at ETH Zürich, then served as Programme Director and NIH Principal Investigator at the University of Zürich, leading a $2.2M NIH U19 consortium across UZH, ETH Zürich, TGen and UCSF.
He has held go/no-go and budget authority over $3M+ of R&D, advises biotech leaders and investment committees on indication, diligence, partnering and fundraising, and designed and built Kairos end to end.
Advised by an Innosuisse-accredited start-up coach.
The road ahead
A company that logs its forecasts before the outcome should date its own plans too.
Jul 2025
One founder and one conviction: the decisions that make or break a biotech deserve the evidence, the reasoning and a record.
2026
~700K source-traced facts, three studios and 150+ agent tools, designed and built end to end.
On the record
Each one logged before the outcome, with its due date, and scored when it falls due. Never back-filled.
Q4 2026Next
Hosted in Switzerland, planned. Design partners bring a real asset and a real question, and shape what Kairos reads next.
Q1 2027Next
Every probability explained, signal by signal: a base rate that counts the failures, moved only by dated, cited evidence. A time-split benchmark, published with its method.
2027Next
Tamper-evident, and scored as each forecast resolves. A living evidence state per asset: settled, contested, open, superseded.
Horizon
The reasoning layer for drug-development decisions.
Join us
Sightegy is early, Swiss and ambitious. There are four ways in.
Biotech founders, boards, BD and R&D leads
Bring a real asset and a real question. Get briefs on your own programme and a direct line to the founder.
Join the betaPharma BD, data and platform teams
Connect Kairos to your search-and-evaluation work or to your own AI agents, and shape what it reads next.
Partner with usLife-science and deep-tech investors
A built platform, a Swiss base and a dated road to the reasoning layer for drug-development decisions.
Investor conversationsEngineers, scientists and builders
We are looking for a technical co-founder and an early team to take Kairos from platform to product.
Start a conversation